Evidence map›Paper›PMID 35128282›Full record

ArticleACS omega2022

Determination of Hepatic Iron Deposition in Drug-Induced Liver Fibrosis in Rats by Confocal Micro-XRF Spectrometry.

Qianqian Xu, Wenjing Xia, Lazhen Zhou, Zhengwei Zou, Qiuxia Li, Lijun Deng, Sha Wu, Tao Wang, Jingduo Cui, Zhiguo Liu and 3 more

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Ways to Measure Metals: From ICP-MS to XRF.Current environmental health reports · 2025
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Qianqian XuCollege of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
Wenjing XiaCollege of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
Lazhen ZhouCollege of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
Zhengwei ZouKey Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, Ganzhou 341000, China.
Qiuxia LiCollege of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
Lijun DengCollege of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
Sha WuCollege of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
Tao WangCollege of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.
Jingduo CuiCollege of Nuclear Science and Technology, Beijing Normal University, Beijing 100875, China.
Zhiguo LiuCollege of Nuclear Science and Technology, Beijing Normal University, Beijing 100875, China.
Tianxi SunCollege of Nuclear Science and Technology, Beijing Normal University, Beijing 100875, China.
Junsong YeKey Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, Ganzhou 341000, China.
Fangzuo LiCollege of Medical Information Engineering, Gannan Medical University, Ganzhou 341000, China.ORCID https://orcid.org/0000-0001-5436-6284
Gannan Medical University · CNBeijing Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver fibrosis is the intermediate process and inevitable stage of the development of chronic liver disease into cirrhosis. Reducing the degree of liver fibrosis plays an extremely important role in treating chronic liver disease and preventing liver cirrhosis and liver cancer. The formation of liver fibrosis is affected by iron deposition to a certain extent, and excessive iron deposition further induces liver cirrhosis and liver cancer. Herein, confocal microbeam X-ray fluorescence (μ-XRF) was used to determine the intensity and biodistribution of iron deposition at different time points in the process of liver fibrosis induced by thioacetamide (TAA) in rats. To our best knowledge, this is the first study using confocal μ-XRF to analyze hepatic iron deposition in hepatic fibrosis. The results showed that there are minor and trace elements such as iron, potassium, and zinc in the liver of rats. Continuous injection of TAA solution resulted in increasing liver iron deposition over time. The intensity of iron deposition in liver tissue was also significantly reduced after bone mesenchymal stem cells (BMSCs) were injected. These findings indicated that confocal μ-XRF can be used as a nondestructive and quantitative method of evaluating hepatic iron deposition in hepatic fibrosis, and iron deposition may play an important role in the progression of hepatic fibrosis induced by TAA.

Identifiers

PMID35128282
PMCPMC8811927
OpenAlexW4206991325

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.